Pieter Pannus1,2, Sofie Rutsaert3, Stéphane De Wit4, Sabine D Allard5, Guido Vanham1,2, Basiel Cole3, Coca Nescoi4, Joeri Aerts6, Ward De Spiegelaere7, Achilleas Tsoumanis1, Marie-Madeleine Couttenye8, Natacha Herssens1, Marie-Angélique De Scheerder3, Linos Vandekerckhove3, Eric Florence1. 1. Departments of Clinical and Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. 2. Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium. 3. Department of General Internal Medicine, HIV Cure Research Centre, Ghent University Hospital and Ghent University, Ghent, Belgium. 4. Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium. 5. HIV Reference Centre, Universitair Ziekenhuis Brussel, Brussels, Belgium. 6. Vrije Universiteit Brussel, Brussels, Belgium. 7. Department of Morphology, Faculty of Veterinary Medicine, Ghent University, Ghent, Belgium. 8. Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.
Abstract
INTRODUCTION: Viral remission after analytical treatment interruption (ATI), termed post-treatment control, has been described in a small proportion of HIV-positive patients. This phenomenon has been separately associated to both low levels of HIV-1 proviral DNA as well as cell-associated RNA. We investigated whether the combination of both parameters could help predict delayed viral rebound after treatment interruption (TI). METHODS: We conducted an open single-arm ATI study in four Belgian HIV reference centres from January 2016 to July 2018. Eligible participants were adults who had fewer than 50 HIV-1 RNA copies/mL for more than two years, more than 500 CD4 cells/µL for more than three months, and were in general good health. Consenting participants who had fewer than 66 copies total HIV-1 DNA (t-DNA) and fewer than 10 copies cell-associated HIV-1 unspliced RNA (US-RNA) per million peripheral blood mononuclear cells (PBMCs), interrupted therapy and were monitored closely. Antiretroviral therapy (ART) was resumed after two consecutive viral loads exceeding 1000 copies or one exceeding 10,000 copies/mL. The primary outcome was the proportion of participants with fewer than 50 HIV-1 RNA copies/mL 48 weeks after TI. Secondary outcomes were time to viral rebound, the frequency of serious adverse events (AEs) and evolution of t-DNA and US-RNA after TI. RESULTS: All 16 consenting participants who interrupted therapy experienced rapid viral rebound two to eight weeks after TI. No serious AEs were observed. Levels of t-DNA and US-RNA increased after TI but returned to pre-ATI levels after treatment restart. None of the studied demographic, clinical and biological parameters were predictive of time of viral rebound. CONCLUSIONS: The combination of low levels of t-DNA and US-RNA in PBMCs, corresponding respectively to a small and transcriptionally silent viral reservoir, is not predictive of viral remission after TI in patients on ART.
INTRODUCTION: Viral remission after analytical treatment interruption (ATI), termed post-treatment control, has been described in a small proportion of HIV-positivepatients. This phenomenon has been separately associated to both low levels of HIV-1 proviral DNA as well as cell-associated RNA. We investigated whether the combination of both parameters could help predict delayed viral rebound after treatment interruption (TI). METHODS: We conducted an open single-arm ATI study in four Belgian HIV reference centres from January 2016 to July 2018. Eligible participants were adults who had fewer than 50 HIV-1 RNA copies/mL for more than two years, more than 500 CD4 cells/µL for more than three months, and were in general good health. Consenting participants who had fewer than 66 copies total HIV-1 DNA (t-DNA) and fewer than 10 copies cell-associated HIV-1 unspliced RNA (US-RNA) per million peripheral blood mononuclear cells (PBMCs), interrupted therapy and were monitored closely. Antiretroviral therapy (ART) was resumed after two consecutive viral loads exceeding 1000 copies or one exceeding 10,000 copies/mL. The primary outcome was the proportion of participants with fewer than 50 HIV-1 RNA copies/mL 48 weeks after TI. Secondary outcomes were time to viral rebound, the frequency of serious adverse events (AEs) and evolution of t-DNA and US-RNA after TI. RESULTS: All 16 consenting participants who interrupted therapy experienced rapid viral rebound two to eight weeks after TI. No serious AEs were observed. Levels of t-DNA and US-RNA increased after TI but returned to pre-ATI levels after treatment restart. None of the studied demographic, clinical and biological parameters were predictive of time of viral rebound. CONCLUSIONS: The combination of low levels of t-DNA and US-RNA in PBMCs, corresponding respectively to a small and transcriptionally silent viral reservoir, is not predictive of viral remission after TI in patients on ART.
Authors: Geoffrey Ndikabona; John Bosco Alege; Nicholas Sebuliba Kirirabwa; Derrick Kimuli Journal: BMC Public Health Date: 2021-12-18 Impact factor: 3.295
Authors: Karen L Diepstra; Liz Barr; David Palm; Evelyn Hogg; Katie R Mollan; Laney Henley; Angela M Stover; Jane M Simoni; Jeremy Sugarman; Brandon Brown; John A Sauceda; Steven Deeks; Lawrence Fox; Rajesh T Gandhi; Davey Smith; Jonathan Z Li; Karine Dubé Journal: AIDS Res Hum Retroviruses Date: 2021-02-16 Impact factor: 1.723
Authors: Pablo Tebas; Julie K Jadlowsky; Pamela A Shaw; Lifeng Tian; Erin Esparza; Andrea L Brennan; Sukyung Kim; Soe Yu Naing; Max W Richardson; Ashley N Vogel; Colby R Maldini; Hong Kong; Xiaojun Liu; Simon F Lacey; Anya M Bauer; Felicity Mampe; Lee P Richman; Gary Lee; Dale Ando; Bruce L Levine; David L Porter; Yangbing Zhao; Don L Siegel; Katharine J Bar; Carl H June; James L Riley Journal: J Clin Invest Date: 2021-04-01 Impact factor: 19.456
Authors: Evelyn Y Bonney; Helena Lamptey; James O Aboagye; Christopher Zaab-Yen Abana; Anthony T Boateng; Darius N K Quansah; Adjoa Obo-Akwa; Vincent J Ganu; Peter Puplampu; George B Kyei Journal: J Virus Erad Date: 2021-01-01
Authors: Elias P Rosen; Claire Deleage; Nicole White; Craig Sykes; Catherine Brands; Lourdes Adamson; Paul Luciw; Jacob D Estes; Angela D M Kashuba Journal: J Int AIDS Soc Date: 2022-04 Impact factor: 6.707
Authors: Taina T Immonen; Christine M Fennessey; Leslie Lipkey; Abigail Thorpe; Gregory Q Del Prete; Jeffrey D Lifson; Miles P Davenport; Brandon F Keele Journal: PLoS Pathog Date: 2021-06-18 Impact factor: 6.823